About Pirtobrutinib API
Therapeutic CategoryAnti-Cancer/ Oncology

CAS Number
2101700-15-4
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Pirtobrutinib binds reversibly to the BTK protein in the ATP pocket and does not depend on C481. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations. A visualization of pirtobrutinib binding reversibly to the BTK protein with an exploded view showing the ATP pocket.
Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!